Recombinant Human RelA/NFkB p65 Protein，His

RelA, commonly known as NF-κB p65, is a pivotal transcription factor that regulates various biological processes, including inflammation, immune responses, and cell proliferation. Its activation is crucial for the expression of a wide array of genes involved in these processes. Under normal conditions, NF-κB is sequestered in the cytoplasm in an inactive form bound to IκB proteins. Upon cellular stimulation by cytokines, growth factors, and other signals, IκB proteins are phosphorylated and subsequently degraded, allowing NF-κB to translocate to the nucleus and initiate gene transcription. Dysregulation of NF-κB signaling has been implicated in numerous diseases, including cancer, autoimmune disorders, and chronic inflammatory diseases, making it a significant target for therapeutic intervention. The need for engineered RelA/NF-κB p65 recombinant proteins has arisen from the necessity to study its structure, function, and regulatory mechanisms in detail. By producing recombinant p65 proteins, researchers can investigate its binding affinity to DNA, interactions with other proteins, post-translational modifications, and its roles in specific signaling pathways. Consequently, studying this protein provides insights into its dual role as a transcription regulator and its potential as a target for drug development aimed at modulating its activity in pathological conditions. Overall, the research surrounding RelA/NF-κB p65 recombinant proteins is vital for advancing our understanding of its biological implications and developing effective therapeutic strategies against diseases linked to its dysfunction.